Loss of FGFR4 promotes the malignant phenotype of PDAC

Oncogene. 2022 Sep;41(38):4371-4384. doi: 10.1038/s41388-022-02432-5. Epub 2022 Aug 13.

Abstract

Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4 in the definition of aggressive PDAC phenotypes. We found that the expression of FGFR4 is exclusively detected in epithelial cells, significantly elevated in the classical PDAC subtype, and associates with better outcomes. In highly aggressive basal-like/squamous PDAC, reduced FGFR4 expression aligns with hypermethylation of the gene and lower levels of histone marks associated with active transcription in its regulatory regions. Conversely, FGFR1 has more promiscuous expression in both normal and malignant pancreatic tissues and is strongly associated with the EMT phenotype but not with the basal-like cell lineage. Regardless of the genetic background, the increased proliferation of FGFR4-depleted PDAC cells correlates with hyperactivation of the mTORC1 pathway both in vitro and in vivo. Downregulation of FGFR4 in classical cell lines invariably leads to the enrichment of basal-like/squamous gene programs and is associated with either partial or full switch of phenotype. In sum, we show that endogenous levels of FGFR4 limit the malignant phenotype of PDAC cells. Finally, we propose FGFR4 as a valuable marker for the stratification of PDAC patients.

MeSH terms

  • Carcinoma, Pancreatic Ductal* / pathology
  • Carcinoma, Squamous Cell*
  • Humans
  • Mechanistic Target of Rapamycin Complex 1 / genetics
  • Pancreatic Neoplasms* / pathology
  • Phenotype
  • Receptor, Fibroblast Growth Factor, Type 4 / genetics

Substances

  • FGFR4 protein, human
  • Receptor, Fibroblast Growth Factor, Type 4
  • Mechanistic Target of Rapamycin Complex 1

Supplementary concepts

  • Pancreatic Carcinoma